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Modern insulin regimens for the treatment of type 1 diabetes are highly
individualized. The concept of an individually tailored medicine accounts for a
broad variety of different insulin regimens applied. Despite clear
recommendations for insulin management in children and adolescents with
type 1 diabetes there is little distinctiveness about concepts and the
nomenclature is confusing. Even among experts similar terms are used for
different strategies. The aim of our review – based on the experiences of the
Hvidoere Study Group (HSG) – is to propose comprehensive definitions for
current insulin regimens reflecting current diabetes management in childhood
and adolescence. The HSG – founded in 1994 – is an international group
representing 24 highly experienced pediatric diabetes centers, from Europe,
Japan, North America and Australia. Different benchmarking studies of the
HSG revealed a broad variety of insulin regimens applied in each center,
respectively. Furthermore, the understanding of insulin regimens has been
persistently different between the centers since more than 20 yr. Not even the
terms ‘conventional’ and ‘intensified therapy’ were used consistently among all
members. Besides the concepts ‘conventional’ and ‘intensified’, several other
terms for the characterization of insulin regimens are in use: Basal Bolus
Concept (BBC), multiple daily injections (MDI), and flexible insulin therapy
(FIT) are most frequently used, although none of these expressions is clearly or
consistently defined. The proposed new classification for insulin management
will be comprehensive, simple, and catchy. Currently available terms were
included. This classification may offer the opportunity to compare therapeutic
strategies without the currently existing confusion on the insulin regimen.
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Modern insulin regimens for the treatment of type
1 diabetes are highly individualized. The concept of
an individually tailored medicine (1) accounts for a
broad variety of different insulin regimens applied (2).
Flexible, personalized insulin preparations and fixed
premixed preparations are in use (3). Despite clear
recommendations for insulin management in children
and adolescents with type 1 diabetes (4, 5) there is little
distinctiveness about concepts and the nomenclature is
confusing. Even among experts similar terms are used
for different strategies. The aim of this paper – based
on the experiences of the Hvidoere Study Group
(HSG) – is to propose comprehensive definitions for
current insulin regimens reflecting current diabetes
management in childhood and adolescence.
Historical development
Commonly accepted is the differentiation between
‘conventional therapy (CT)’ and ‘intensive therapy’
since the results of the Diabetes Control and Com-
plications Trial (DCCT) study have been published in
September 1993 (6). The terms, however, were already
used earlier. Different types of treatment in the context
of micro vascular complications were mentioned
already in the 1960s (7). Even earlier, in the 1930s, the
German pediatrician Karl Stolte, one of the pioneers
of modern insulin therapy, differentiated between clas-
sical insulin concepts and more liberal strategies with
dose adjustment to varying carbohydrate amount of
meals (8). CT according to the DCCT definition means
one or two daily insulin injections including premixed
intermediate and rapid acting insulins and daily
self-monitoring of urine or blood glucose. In contrast,
intensive therapy is defined as administration of insulin
three or more times daily by injection or external pump.
The dosage is adjusted according to the results of self-
monitoring of blood glucose performed at least four
times per day, dietary intake and anticipated exercise
(6). This definition already discloses one of the difficul-
ties defining insulin regimens: the number of injections,
the insulin types and blood glucose measurements can
all be used as criteria for a classification.
Insulin preparations
As a consequence of the DCCT (6) and an implication
of subsequent publications (9) intensive insulin
management has been established as a standard for
the treatment of children with type 1 diabetes. A broad
variety of types of insulin is available (Table 1) to
implement best tailored management to the individual
need of each child or adolescent (10).
Experiences from the HSG
The Hvidoere Study Group (HSG) – founded in
1994 – is an international group representing 24 highly
experienced pediatric diabetes centers, from Europe,
Japan, North America, and Australia. The group
established a research network to carry out multicenter
investigations to compare data on childhood
diabetes. They published several benchmarking studies
that revealed considerable differences in metabolic
outcomes among the participating centers (11–13).
However, it was difficult to attribute these differences
to the different insulin strategies applied (14, 15).
Besides the proportion between short to intermediate-
acting insulin, the circadian rhythm of insulin
sensitivity, the principles of estimating or calculating
carbohydrates, protein and fat, practical aspects such
as the injection area or the device used (syringe, pen,
pump) may all be significant parameters considered
when comparing metabolic outcome cross centers.
Other relevant key factors for therapy success are the
quality and extent of education for patients and their
families and the supportive behavioral management
over a long time to improve self-efficacy in a
child’s life.
Consensus finding
Consensus of experts is considered to be the least
credible form of evidence and thus usually is rated
in the lowest category of evidence by most health
systems, e.g., the U.S. Preventive Services Task Force
(16) or the UK National Health Service (17). Using
individual clinical expertise is not per se inconsistent
with evidence-based medicine (18), however for
the matter of comparisons and the development of
recommendations individualized medical concepts
are obstacles. The application and classification of
different insulin regimens (19) discloses the dilemma
between the striving for individually tailored concepts
on the one hand and evidence-based concepts on the
other hand.
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Table 1. Insulin type and activities (Steck et al. 10)
Type of insulin
Onset of
action
Peak
effect
Total
duration
Short and rapid acting
Regular 30–60 min 2–4 h 6–9 h
Aspart, lispro,
and glulisine
10–15 min 30–90 min 3–4 h
Intermediate acting
NPH 1–2 h 3–8 h 12–15 h
Basal insulin
Glargine 1–2 h No peak 24 h
Detemir 1–2 h No peak 20 h
Premixed insulins
70/30
NPH/regular
30–60 min 3–8 h 12–15 h
75/25
NPH/lispro
10–15 min 30 min–8 h 12–15 h
NPH, Neutrale Protamine Hagedorn.
Currently applied terms
Different benchmarking studies of the HSG revealed a
broad variety of insulin regimens applied in each center,
respectively (14, 20). Furthermore, the understanding
of insulin regimens has been persistently different
between the centers since more than 20 yr. Not even the
terms ‘conventional’ and ‘intensified therapy’ were used
consistently among all members. However, most of the
group agreed that CT nowadays means: 1–2 injections
per day, insulin types, and doses determine when and
what the patients need to eat. In contrast, intensified
conventional insulin therapy (ICT) consists of three
or more injections per day; insulin administration
is adjusted to mealtime (circadian rhythm of insulin
sensitivity) and amount of food.
Besides the concepts ‘conventional’ and ‘intensified’,
several other terms for the characterization of insulin
regimens are in use: Basal Bolus Concept (BBC),
multiple daily injections (MDI), and flexible insulin
therapy (FIT) are most frequently used, although none
of these expressions is clearly or consistently defined.
Available recommendations
Frequently used regimens are described in detail by
the International Society for Pediatric and Adolescent
Diabetes (ISPAD) Clinical Practice Consensus Guide-
lines (4, 5). Injection frequency, insulin formulations
and preparations, dose adjustments are part of
this report. The American Diabetes Association
(ADA) Recommendations concentrate on MDI (3–4
injections per day of basal and prandial insulin) for the
treatment of type 1 diabetes (21). The International
Diabetes Federation (IDF) Guidelines emphasize the
dynamic relationship between carbohydrate intake,
physical activity, and insulin using the term basal bolus
regimen (22).
Table 2. Classification of insulin regimens (according to
administration)
Category I: Fixed insulin dose regimens
Definition: set insulin dosage not or minimally adjusted to
daily varying meals. Insulin dosage defines the
subsequent mealtimes and their amount of
carbohydrates.
Insulin administration: 1–2 injections per day.
Included: Basal insulin only/premixed insulin
only/free-mixed insulin combinations.
Category II: Glucose and meal-adjusted injection regimens
Definition: administration of insulin according to results of
self-monitoring of glucose and intended time of meal
intake (no set dose). Insulin dosage allows a varying
amount of carbohydrates following the injections.
Insulin administration: three or more injections.
Included: ICT/BBC/MDI/FIT.
Category III: Pump therapy
Definition: continuous subcutaneous insulin infusion and
administration of insulin according to results of
self-monitoring of glucose and intended time of meal
intake. Insulin dosage allows a varying amount of
carbohydrates following the injections.
Insulin administration: continuous insulin administration for
basal insulin.
BBC, Basal Bolus Concept; FIT, flexible insulin therapy; ICT,
intensified conventional insulin therapy; MDI, multiple daily
injections.
In some countries the category I regimen is relatively
uncommon. In previous studies of the Hvidoere Study Group
category II was the regimen most frequently applied. The
option to adjust insulin for the glucose but using a fixed
or prescribed meal content may be considered a simplified
version of category II.
Difficulties defining insulin regimens
The criteria for characterizing different strategies
are diverse. Whereas some are focused on insulin
administration, others include the proportion of short-
to intermediate-acting insulin in their definition. For
none of the definitions there is a clear and scientifically
proven association to glycemic control. For matters
of comparison and benchmarking studies, however, it
is crucial to characterize the insulin strategy applied
in each center respectively. These difficulties and
the need for a generally accepted definition are
obvious.
Proposal for classifying insulin regimens
A new classification should be comprehensive, simple,
and catchy. Currently available terms should be
included. On the basis of experience of former
benchmarking studies among different international
centers of excellence, a new classification of insulin
regimens is proposed. Insulin regimens were divided
into three categories (fixed insulin dose regimens,
glucose and meal-adjusted regimens, pump therapy)
according to the administration of insulin (Table 2).
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Perspectives
This proposed classification for insulin management
may offer the opportunity to compare therapeutic
strategies without the currently existing confusion on
the insulin regimen.
Best therapeutic strategies will depend on the
regimen and the implementation of these regimens.
Cornerstone remains the quality and extent of patient
education and skill training (carbohydrate counting,
home monitoring of blood glucose values, etc.),
ensuring the patients’ efficacy in realizing all steps of
these different therapies in their daily life.
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